Breast Cancer International Research Group

TRIO (Translational Research in Oncology), formerly known as the Breast Cancer International Research Group (BCIRG), is a global academic clinical research organization (ARO) dedicated to advancing cancer treatments. Founded in 1997 by Dr. Dennis Slamon, the organization is renowned for its leadership in pivotal clinical trials, most notably the BCIRG 006 trial which established trastuzumab as a standard of care for HER2-positive breast cancer. TRIO operates as a non-profit entity, bridging the gap between academic innovation and pharmaceutical development through a vast network of over 2,000 international investigators. The organization provides comprehensive trial management services, including protocol design, global site monitoring, and integrated translational research. By focusing on targeted therapies and innovative trial designs, TRIO has played a critical role in the regulatory approval of several major oncology drugs. Its global footprint includes operations in North America, Europe, and South America, facilitating large-scale international oncology studies.